What is the recommended diagnostic and therapeutic approach to Evans syndrome?

How to Approach Evans Syndrome

Evans syndrome requires aggressive front-line therapy with prednisone 1 mg/kg/day (with or without IVIG), followed by rituximab as second-line treatment, while conducting extensive diagnostic evaluation to identify underlying conditions that may alter management.

Diagnostic Approach

Essential Initial Workup

Perform comprehensive diagnostic testing to confirm Evans syndrome and identify secondary causes 1:

• Complete blood count with differential, peripheral blood smear, and reticulocyte count
• Direct antiglobulin test (DAT) to confirm autoimmune hemolytic anemia (AIHA) - positive for IgG indicates warm AIHA 2
• Bone marrow evaluation - recommended by consensus to assess for underlying disorders 1
• CT scan - to evaluate for lymphoproliferative disorders 1

Screen for Secondary Causes

Evans syndrome can be primary (idiopathic) or secondary to underlying conditions 2. Test for:

• Infections: HIV, hepatitis B, hepatitis C, CMV, H. pylori 3, 4
• Autoimmune diseases: antiphospholipid antibodies, lupus markers
• Lymphoproliferative disorders: lymphoma, chronic lymphocytic leukemia
• Primary immunodeficiencies: particularly in younger patients or those with recurrent infections 1

Key Clinical Features to Document

• Personal and family history of autoimmunity 3, 4
• Medication history - rule out drug-induced cytopenias
• Bleeding symptoms and thrombotic events - Evans syndrome carries thrombotic risk despite thrombocytopenia 5
• Infection history - influences treatment choices

Treatment Algorithm

First-Line Therapy

Prednisone is the cornerstone of initial treatment 1:

• Dosing: 1 mg/kg/day (range 0.5-2 mg/kg/day) orally 3, 4
• Duration differs by cytopenia:
  • For ITP component: 2-4 weeks, then taper over 4-6 weeks 3, 4
  • For AIHA component: longer duration and slower taper recommended 1

Add IVIG when rapid platelet increase needed 3, 4:

• Dose: 1 g/kg as one-time dose, may repeat if necessary
• Particularly important if platelet count <25,000/μL or active bleeding

Second-Line Therapy

Rituximab is strongly recommended as second-line treatment 1:

• First-line in cold-type AIHA (if present)
• Second-line for warm AIHA and ITP after corticosteroid failure
• Especially recommended if:
  • Antiphospholipid antibodies present
  • Previous thrombotic events
  • Associated lymphoproliferative disease 1

Contraindications to rituximab 1:

• Active severe infections
• Underlying immunodeficiency

Alternative second-line options:

• Thrombopoietin receptor agonists (TPO-RAs): recommended for chronic ITP component, especially with history of grade 4 infection 1
• Fostamatinib: suggested for patients with previous thrombotic events 1

Third-Line and Refractory Disease

If corticosteroids and rituximab fail 1:

• Immunosuppressive agents: mycophenolate mofetil, azathioprine, cyclosporine (moved to third-line)
• Rituximab plus bendamustine: for Evans syndrome secondary to lymphoproliferative disorders 1
• Splenectomy: discouraged in patients with immunodeficiency or severe infections 1

For severe refractory cases 3, 4:

• Horse or rabbit ATG plus cyclosporine
• Cyclophosphamide
• Eltrombopag plus supportive care

Special Considerations

Thrombotic Risk Management

Evans syndrome paradoxically carries thrombotic risk despite thrombocytopenia 5:

• Risk factors include: hemolysis, immune dysregulation, prior splenectomy, TPO-RA exposure, antiphospholipid antibodies
• Consider thromboprophylaxis once platelet count recovers
• Screen for antiphospholipid antibodies in all patients

Supportive Care

• Transfusion thresholds: Use clinical judgment; severe thrombocytopenia alone doesn't mandate platelet transfusion without bleeding
• Recombinant erythropoietin: recommended in AIHA with inadequate reticulocyte response 1
• Infection prophylaxis: Consider in patients on intensive immunosuppression

Treatment of Underlying Conditions

If secondary Evans syndrome identified:

• HIV-associated: Treat HIV with antivirals first unless clinically significant bleeding 2
• HCV-associated: Consider antiviral therapy; monitor platelets closely as interferon may worsen thrombocytopenia 2
• H. pylori-positive: Eradicate infection 2
• Lymphoproliferative disorders: Treat underlying malignancy

Common Pitfalls

• Failing to check DAT - essential to confirm AIHA component
• Inadequate evaluation for secondary causes - 25% have underlying conditions 6
• Using same steroid duration for both cytopenias - AIHA requires longer treatment than ITP 1
• Overlooking thrombotic risk - anticoagulation may be needed despite low platelets 5
• Premature splenectomy - now relegated to later-line therapy given infection risk 1